Viatris, Inc. (VTRS)
17.60
+0.14
(+0.80%)
USD |
NASDAQ |
Oct 02, 16:00
17.60
0.00 (0.00%)
After-Hours: 20:00
Viatris Enterprise Value : 32.55B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 32.55B |
| October 01, 2026 | 32.39B |
| September 30, 2026 | 32.69B |
| September 29, 2026 | 33.15B |
| September 28, 2026 | 33.32B |
| September 25, 2026 | 32.81B |
| September 24, 2026 | 32.34B |
| September 23, 2026 | 31.99B |
| September 22, 2026 | 32.06B |
| September 21, 2026 | 31.97B |
| September 18, 2026 | 31.80B |
| September 17, 2026 | 32.01B |
| September 16, 2026 | 31.88B |
| September 15, 2026 | 31.45B |
| September 14, 2026 | 31.46B |
| September 11, 2026 | 31.29B |
| September 10, 2026 | 31.14B |
| September 09, 2026 | 31.28B |
| September 08, 2026 | 31.41B |
| September 04, 2026 | 31.72B |
| September 03, 2026 | 31.79B |
| September 02, 2026 | 31.96B |
| September 01, 2026 | 31.43B |
| August 31, 2026 | 31.29B |
| August 28, 2026 | 31.09B |
| Date | Value |
|---|---|
| August 27, 2026 | 31.73B |
| August 26, 2026 | 31.68B |
| August 25, 2026 | 31.53B |
| August 24, 2026 | 31.32B |
| August 21, 2026 | 31.07B |
| August 20, 2026 | 30.84B |
| August 19, 2026 | 30.98B |
| August 18, 2026 | 30.90B |
| August 17, 2026 | 30.97B |
| August 14, 2026 | 30.97B |
| August 13, 2026 | 30.75B |
| August 12, 2026 | 30.82B |
| August 11, 2026 | 31.02B |
| August 10, 2026 | 31.02B |
| August 07, 2026 | 31.20B |
| August 06, 2026 | 31.04B |
| August 05, 2026 | 32.61B |
| August 04, 2026 | 32.66B |
| August 03, 2026 | 32.58B |
| July 31, 2026 | 32.50B |
| July 30, 2026 | 32.73B |
| July 29, 2026 | 32.80B |
| July 28, 2026 | 32.85B |
| July 27, 2026 | 32.59B |
| July 24, 2026 | 32.13B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc. | 210.23B |
| Eli Lilly & Co. | 1.122T |
| Merck & Co., Inc. | 403.00B |
| Bristol Myers Squibb Co. | 158.92B |
| Johnson & Johnson | 644.86B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -118.80M |
| Revenue (Quarterly) | 3.762B |
| Total Expenses (Quarterly) | 3.881B |
| EPS Diluted (Quarterly) | -0.1021 |
| Gross Profit Margin (Quarterly) | 41.92% |
| Profit Margin (Quarterly) | -3.16% |
| Earnings Yield | -2.03% |
| Operating Earnings Yield | 6.97% |
| Normalized Earnings Yield | 2.868 |